Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P41597
UPID:
CCR2_HUMAN
Alternative names:
Monocyte chemoattractant protein 1 receptor
Alternative UPACC:
P41597; A0AVQ3; B2RMT0; O95950; Q4VBL2
Background:
C-C chemokine receptor type 2 (CCR2), also known as Monocyte chemoattractant protein 1 receptor, plays a pivotal role in immune responses. It binds to chemokines like CCL2, CCL7, and CCL12, mediating chemotaxis and migration of monocytes and macrophages through the PI3K cascade. CCR2 also facilitates T-cell differentiation into Th17 cells during inflammation and is involved in peripheral nerve injury-induced neuropathic pain. Additionally, it serves as an alternative coreceptor for HIV-1 infection.
Therapeutic significance:
Understanding the role of C-C chemokine receptor type 2 could open doors to potential therapeutic strategies, particularly in managing inflammatory conditions, neuropathic pain, and HIV-1 infection.